Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections

Clinical Therapeutics
Bruce W Bode

Abstract

Replicating endogenous insulin production is the goal of treatment for diabetes mellitus (DM) and is necessary to minimize the risk of vascular complications. The 2 main methods of achieving this goal are continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDIs) comprising basal and prandial injections. The objective of this article was to discuss the use of a rapid-acting insulin analogue, insulin aspart, in CSII and MDI compared with other insulins in adult patients with type 1 or type 2 DM. This article was based on a presentation given by the author at a satellite symposium entitled "Realising the Value of Modern Insulins: Reaching Further with Rapid-Acting Insulin Analogues" that was convened during the XIXth World Diabetes Congress, December 3, 2006, in Cape Town, South Africa. In patients with type 1 DM, CSII using the rapid-acting insulin analogue insulin aspart has been reported in clinical trials to improve glycemic control compared with MDI therapy using neutral protamine Hagedorn plus insulin aspart (for basal and mealtime coverage, respectively). In patients with type 2 DM, the CSII and MDI regimens offered similar efficacy and tolerability; CSII therapy may be less burdensome, however, w...Continue Reading

Citations

Aug 21, 2012·Current Diabetes Reports·Masakazu HiroseKatie Weinger
Jan 29, 2010·Diabetes Technology & Therapeutics·Andrea E ScaramuzzaGian Vincenzo Zuccotti
Sep 3, 2010·Diabetes Technology & Therapeutics·Jothydev KesavadevViswanathan Mohan
Nov 24, 2011·Diabetes Technology & Therapeutics·Scott D SharrowMichael A Dobbins
Jan 6, 2009·Diabetes, Obesity & Metabolism·B SheldonJ Wright
Oct 16, 2009·Journal of the American Pharmacists Association : JAPhA·Scott Drab
Oct 31, 2012·Journal of Medical Primatology·Xi JinYanrong Lu
Dec 18, 2012·Diabetes, Obesity & Metabolism·S C L GoughM Davies
Aug 4, 2015·Canadian Journal of Diabetes·Vincent C Woo
Aug 10, 2016·Journal of Diabetes Research·A SchaschkowE Maillard
Jan 31, 2017·Diabetes Technology & Therapeutics·Bruce W BodeNan Vint
Jun 2, 2010·Journal of Diabetes Science and Technology·Jean-Louis Selam
Jun 25, 2018·Diabetes Care·Guillermo E Umpierrez, David C Klonoff
Oct 15, 2010·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Chaker Ben SalemKamel Bouraoui
Jan 25, 2013·The Nurse Practitioner·Betsy B Dokken
Jul 30, 2016·Diabetology & Metabolic Syndrome·Roberto Pecoits-FilhoSergio Vencio
Dec 8, 2010·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Bruce W Bode
Feb 28, 2020·The Cochrane Database of Systematic Reviews·Meaghan LunneyPietro Ravani

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.